CLAIMS

1. Use of a combination of (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and brimonidine or a salt thereof in the manufacture of a medicament for the prevention or treatment of glaucoma or ocular hypertension, wherein the combination is incorporated in a single dosage form.

2. Use of a combination of (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and brimonidine or a salt thereof in the manufacture of a medicament for the prevention or treatment of glaucoma or ocular hypertension, wherein the combination is such that the (S)-(-)-1-(4-fluoro-5- isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, and the brimonidine or a salt thereof are independently formulated and are to be administered simultaneously.

3. Use of a combination of (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and brimonidine or a salt thereof in the manufacture of a medicament for the prevention or treatment of glaucoma or ocular hypertension wherein a formulation comprising (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine is to be administered as a first agent and a formulation comprising brimonidine or a salt thereof is to be administered as a second agent.